Biomarkers Market Around Globe: Growth, Development, Trends, Demand, Share, Analysis and Forecast

 

Contact Information
Coherent Market Insights
Coherent Market Insights
Seattle,
WA - 98154
United States
+1 02067016702
satish@coherentmarketinsights.com
 
Biomarkers are used for diagnosis and drug development, as these biomarkers can indicate diseases in the body. Furthermore, biomarkers can be any specific cells, molecules, genes or gene products, enzymes or hormones. Biomarker-based test are precise and rapid, which help in early prediction of susceptibility, prognosis, diagnosis, and treatment of disease. Hence, increasing research and development activities for identifying new biomarkers to diagnose or treat diseases is expected to be major factor growth of the market.

Biomarker are required for personalized medicine as it helps to identify the unique characteristics of the disease and helps to tailor medicine according to the need of patients. Hence, to cater to demand for personalized medicines, pharmaceutical companies are investing in R&D, which is expected to lead to identification of novel biomarkers, thus aiding in growth of the market.

Request Sample Copy Of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1530

Market Dynamics

The global biomarkers market is projected to witness significant growth over the forecast period, owing to rapid advancements in technology for development of novel biomarker. For instance, in February 2018, FDA granted marketing authorization to Banyan Biomarkers, Inc. for the first diagnostic blood test for traumatic brain injury named Banyan BTI. Such innovations, targeting different indications, is expected to drive biomarkers market growth in the near future.

Key features of the study:

This report provides in-depth analysis of the biomarkers market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2017 – 2025, considering 2016 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global biomarkers market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies

Moreover, pharmaceutical companies have started outsourcing the complex bio analysis not only to cut down costs, however, to take advantage of specialized expertise to improve efficiency in drug development process. For instance, in March 2018, the SenzaGen signed a key license agreement with Burlesson Research Technologies, Inc., (BRT)—a contract research organization in the U.S., specializing in immunotoxicology. This agreement, will provide BRTs 'GARD' to a broader market. GARD is a group of tests for assessing chemical sensitizers, where the test uses genetic biomarkers for over 200 genes, which cover an entire immune reaction and are relevant to predicting the risk of hypersensitivity. Such advancement and innovation by CROs is expected to favor growth of biomarkers market in the near future.

The biomarkers market is estimated to be valued at US$ 29,518.2 Mn in 2017 and is expected to witness a robust CAGR of 13.6% during the forecast period (2017-2025).

Key players are involved in new product launches to cater to increasing demand for biomarkers. For instance, in 2016 Abbott Laboratories launched Point-of-Care i-STAT Alinity, an innovative, handheld blood testing platform. Some of the other key players in biomarkers market include Medtronic plc, BG Medicine, Inc., F. Hoffmann-La Roche Ltd., Seimens Healthnineers, Nexus-DX, Qiagen N.V., and Lifesign LLC.

Click To Read More On Biomarkers Market

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
For more information, visit: https://www.coherentmarketinsights.com/


Biomarkers Market, Biomarkers Market Share, Biomarkers Market Size,

 

If you have any questions regarding information in this press release, please contact the person listed in the Contact / Company information box of this page. Please do not attempt to contact Market Press Release. We will be unable to assist you with any information regarding this release. Market Press Release disclaims any content contained in this press release.